Additional evaluation is required to determine its clinical utility.”
“We introduce magnetic torque tweezers, which enable direct single-molecule measurements of torque. Our measurements of the effective torsional stiffness C of dsDNA indicated a substantial force dependence, with C = similar to 40 nm at low forces up to C LY3023414 = similar to 100 nm at high forces. The initial torsional stiffness of RecA filaments was nearly twofold larger
than that for dsDNA, yet at moderate torques further build-up of torsional strain was prevented.”
“Ablation outcomes were investigated in patients with and without statin pretreatment before cardiac surgery with concomitant surgical ablation for atrial fibrillation (AF). A prospective cohort study was performed containing 149 patients (n=73 statin group vs. n=76 control group) undergoing on-pump cardiac procedures with surgical ablation for
paroxysmal or persistent AF. Measured outcomes were freedom from AF in the intensive care unit, discharge and at three and six months follow-up and perioperative markers of inflammation (white blood cell count, C-reactive protein). Independent predictors for freedom from AF were assessed. Groups did not differ with respect to EuroSCORE, New York Heart Association class, left atrial size, anti-arrhythmic drug therapy or aortic cross-clamp time. Statin therapy had no impact on postoperative SB202190 ic50 inflammatory markers.
Freedom from AF was more frequent in the statin group at discharge (P=0.07) and after three and six months (P<0.05). Subgroup analysis showed that statin pretreatment was associated with higher rates of freedom from AF for paroxysmal BAY 63-2521 cell line AF at three and six months and for persistent AF after six months (P<0.05). Importantly, statin-pretreatment was independently predictive for freedom from AF at discharge wodds ratio (OR): 3.21; 95% confidence interval (CI): 1.2-8.55; P=0.02] and at three months (OR: 2.91; 95% CI: 1.14-7.45; P=0.026). Statin therapy prior to ablation surgery improves postoperative freedom from AF for paroxysmal and persistent AF in cardiac surgery patients. (C) 2010 Published by European Association for Cardio-Thoracic Surgery. All rights reserved.”
“Since the 1970s advances in science and technology during each succeeding decade have renewed the expectation of efficient, reliable automatic epileptiform spike detection (AESD). But even when reinforced with better, faster tools, clinically reliable unsupervised spike detection remains beyond our reach.\n\nExpert-selected spike parameters were the first and still most widely used for AESD. Thresholds for amplitude, duration, sharpness, rise-time, fall-time, after-coming slow waves, background frequency, and more have been used. It is still unclear which of these wave parameters are essential, beyond peak-peak amplitude and duration.